Inventiva S.A. IVA

Company Overview

Inventiva S.A. is a French clinical-stage biopharmaceutical company focused on the research and development of oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), rare diseases, and other conditions with significant unmet medical need. The company operates within the biotechnology and pharmaceutical industries and is publicly traded on Euronext Paris and the Nasdaq Global Market under the ticker IVA. Its primary value driver is the development of lanifibranor, a pan-PPAR agonist being evaluated for the treatment of MASH, a chronic liver disease associated with fibrosis and metabolic disorders.

The company was founded in 2012 as a spin-off from AbbVie’s French research operations following AbbVie’s acquisition of Abbott Laboratories’ pharmaceutical business. Inventiva inherited research infrastructure and scientific programs centered on nuclear receptor biology and fibrosis-related diseases. Over time, the company narrowed its strategic focus toward liver disease and fibrosis therapeutics, positioning itself within a competitive but rapidly expanding market for metabolic and hepatology treatments. Inventiva has also maintained selective research collaborations and out-licensing arrangements to support financing and scientific development.

Business Operations

Inventiva’s operations are primarily centered on drug discovery, clinical development, and regulatory advancement of proprietary therapeutic candidates. Its lead business segment involves the development of lanifibranor, which has advanced into late-stage clinical development for MASH with fibrosis. The company has also pursued earlier-stage programs targeting fibrotic and metabolic diseases through internally developed compounds and collaborative research initiatives. Revenue generation has historically come from collaboration agreements, licensing arrangements, milestone payments, and research partnerships rather than commercialized product sales.

The company operates mainly from France, where it maintains research and corporate functions, while conducting multinational clinical trials across Europe, North America, and other regions. Inventiva has entered partnerships with organizations including CTTQ, Hepalys Pharma, and contract research organizations supporting global clinical operations. The company also benefits from intellectual property covering PPAR modulation technologies and fibrosis-focused therapeutic platforms. Public filings indicate continued reliance on capital markets financing, strategic collaborations, and clinical-development milestones to fund operations.

Strategic Position & Investments

Inventiva’s strategic direction is heavily focused on advancing lanifibranor as a differentiated treatment candidate for MASH, particularly in patients with fibrosis stages associated with elevated risk of progression to cirrhosis and liver failure. The company has emphasized the therapeutic potential of pan-PPAR activation to address multiple disease mechanisms simultaneously, including inflammation, fibrosis, and metabolic dysfunction. This positioning differentiates Inventiva from competitors developing single-pathway approaches in the MASH sector.

The company has invested significantly in global Phase III clinical development and regulatory engagement, including expansion of trial enrollment capabilities and manufacturing preparation. Inventiva has also pursued non-dilutive financing and strategic partnerships to support development efforts. Earlier pipeline activities have included compounds in oncology and rare disease research, though public disclosures indicate the company’s primary operational emphasis remains concentrated on liver disease therapeutics. Data regarding broader portfolio diversification beyond disclosed clinical programs remains limited in public filings.

Geographic Footprint

Inventiva is headquartered in Daix, France, near Dijon, and maintains its principal operational and research activities in France. Its clinical development programs, however, are international in scope, with trials conducted across multiple countries in Europe, North America, and parts of the Asia-Pacific region. The company’s Nasdaq listing has also expanded its visibility among U.S. institutional investors and healthcare-focused capital markets participants.

The company’s operational footprint is primarily research and development driven rather than commercial, as it does not yet market approved therapies. Nevertheless, Inventiva’s partnerships, investor base, and multinational clinical infrastructure provide it with an international presence within the biotechnology sector. Its activities are particularly tied to global hepatology and metabolic disease networks, including clinical research institutions and specialized liver disease centers.

Leadership & Governance

Inventiva’s leadership team combines pharmaceutical research, clinical development, and biotechnology finance experience. The company’s governance structure follows French corporate governance standards applicable to publicly traded companies and includes oversight by a board of directors and executive management team. Strategic leadership has consistently emphasized advancing late-stage clinical assets while preserving financial flexibility through partnerships, equity financing, and disciplined portfolio prioritization.

Key executives publicly identified in company filings and investor materials include:

• Frédéric Cren – Co-founder and Chief Executive Officer
• Pierre Broqua, Ph.D. – Co-founder and Chief Scientific Officer
• Michael Kress – Chief Financial Officer
• Natacha Leclerc – Executive Vice President, Regulatory Affairs and Quality Assurance
• Nicolas Poirier – Executive Vice President, Clinical Development

Management communications and investor presentations indicate a strategic focus on accelerating development of fibrosis and metabolic disease therapies while pursuing regulatory alignment in major pharmaceutical markets.